natgillin/translations-raw huggingface dataset:
These decreases in blood pressure are consistent with the vasodilatory effects of sildenafil, probably due to increased cGMP levels in vascular smooth muscle. 
To znižanje krvnega tlaka je skladno z vazodilatacijskimi učinki sildenafila in je verjetno posledica povečanja koncentracije cGMP v žilnem gladkem mišičju.
Some pack sizes may not be marketed in your country. 
V vaši državi morda na trgu ni vseh navedenih pakiranj.
The mean steady state volume of distribution (Vd) for sildenafil is 105 l, indicating distribution into the tissues. 
Povprečni volumen porazdelitve (Vd) sildenafila v stanju dinamičnega ravnovesja je 105 l, kar kaže, da se porazdeli v tkiva.
Table 1: Medically important adverse reactions reported at an incidence greater than placebo in controlled clinical studies and medically important adverse reactions reported through post-marketing surveillance 
Preglednica 1: Medicinsko pomembni neželeni učinki, ki so bili v nadzorovanih kliničnih študijah zabeležni z večjo pogostnostjo kot pri placebu, in medicinsko pomembni neželeni učinki, zabeleženi med obdobjem postmarketinškega nadzora
You should be aware of how you react to Sildenafil Actavis before you drive or use machinery. 
Zato se morajo bolniki zavedati, kako se odzivajo na zdravilo Sildenafil Actavis, preden vozijo ali upravljajo s stroji.
If you have been told by your doctor that you have an intolerance to some sugars, such as lactose, contact your doctor before taking Sildenafil Actavis. 
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, npr. za laktozo, se pred uporabo zdravila Sildenafil Actavis posvetujte z njim.
Sildenafil Actavis should not be given to individuals under the age of 18. 
Zdravila Sildenafil Actavis ne smejo dobiti osebe, mlajše od 18 let.
Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that Sildenafil Actavis will alter the clearance of substrates of these isoenzymes. 
Ker je največja koncentracija sildenafila v plazmi po priporočenih odmerkih približno 1 mikroM, ni verjetno, da bi Sildenafil Actavis spremenil očistek substratov teh izoencimov.
You should not take Sildenafil Actavis if you do not have erectile dysfunction. 
Zdravila Sildenafil Actavis ne smete jemati, če nimate erektilne disfunkcije.
Prior to prescribing sildenafil, physicians should carefully consider whether their patients with certain underlying conditions could be adversely affected by such vasodilatory effects, especially in combination with sexual activity. 
Preden zdravnik predpiše sildenafil, mora natančno pretehtati, ali bi lahko takšni vazodilatacijski učinki imeli neželene učinke na bolnike, ki imajo določene bolezni, zlasti v kombinaciji s spolno dejavnostjo.
After a single oral dose of 100 mg, the mean maximum total plasma concentration of sildenafil is approximately 440 ng/mL (CV 40%). 
Po enkratnem peroralnem odmerku 100 mg je povprečna največja celotna koncentracija sildenafila v plazmi približno 440 ng/mL (KV 40%).
What Sildenafil Actavis is and what it is used for 
Kaj je zdravilo sildenafil actavis in za kaj ga uporabljamo
Paediatric population Sildenafil Actavis is not indicated for individuals below 18 years of age. 
Pediatrična populacija Zdravilo Sildenafil Actavis ni indicirano pri osebah, mlajših od 18 let.
- If you experience sudden decrease or loss of vision, stop taking Sildenafil Actavis and contact your doctor immediately. 
- če se vam pojavi nenadno poslabšanje ali izguba vida, nehajte jemati zdravilo Sildenafil Actavis in se nemudoma posvetujte z zdravnikom.
Studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside in vitro. 
Študije s človeškimi trombociti kažejo, da sildenafil stopnjuje antiagregacijski učinek natrijevega nitroprusida in vitro.
Sildenafil Actavis will only help you to get an erection if you are sexually stimulated. 
Zdravilo Sildenafil Actavis vam bo pomagalo doseči erekcijo le, če ste spolno stimulirani.
When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP. 
Ko je aktivirana pot NO/cGMP, kot se to zgodi pri spolni stimulaciji, zavrtje PDE5 s sildenafilom poveča koncentracijo cGMP v corpus cavernosum.
Since sildenafil (and its major circulating N-desmethyl metabolite) is 96% bound to plasma proteins, this results in the mean maximum free plasma concentration for sildenafil of 18 ng/mL (38 nM). 
Ker je sildenafil (in njegov glavni krožeči N-dezmetilni presnovek) 96% vezan na beljakovine v plazmi, je povprečna največja koncentracija prostega sildenafila v plazmi 18 ng/mL (38 nM).
In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg) compared to 25% on placebo. 
V študijah s fiksnim odmerkom je bil delež bolnikov, ki so navajali izboljšanje erekcije, 62% (25 mg), 74% (50 mg) oz. 82% (100 mg) v primerjavi s 25% pri bolnikih s placebom.
PDE5 inhibitors, such as Sildenafil Actavis have been shown to increase the hypotensive effects of this medicine. 
Zaviralci PDE5, kot je zdravilo Sildenafil Actavis, dokazano povečujejo hipotenzivne učinke tega zdravila.
Always tell your doctor, pharmacist or nurse if you are taking any of these medicines that are often used for the relief of angina pectoris (or “chest pain”). 
Zdravniku, farmacevtu ali medicinski sestri morate vedno povedati, če jemljete katero od teh zdravil, ki se pogosto uporabljajo za ublažitev angine pektoris (bolečin v prsih).
Stevens-Johnson Syndrome (SJS),* 
Stevens-Johnsonov sindrom (SJS),* toksična epidermalna nekroliza (TEN)*
- If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy 
- če se vam je kdaj vid poslabšal zaradi nearteritične anteriorne ishemične optične nevropatije
Reykjavíkurvegi 76-78 IS-220 Hafnarfjörður Iceland 
Reykjavíkurvegi 76-78 IS-220 Hafnarfjörður Islandija
The following patient groups were represented: elderly (19.9%), patients with hypertension (30.9%), diabetes mellitus (20.3%), ischaemic heart disease (5.8%), hyperlipidaemia (19.8%), spinal cord injury (0.6%), depression (5.2%), transurethral resection of the prostate (3.7%), radical prostatectomy (3.3%). 
Zajete so bile naslednje skupine bolnikov: starejši (19,9%), bolniki z zvišanim krvnim tlakom (30,9%), sladkorno boleznijo (20,3%), ishemično boleznijo srca (5,8%), hiperlipidemijo (19,8%), poškodbo hrbtenjače (0,6%), depresijo (5,2%), transuretralno resekcijo prostate (TURP) (3,7%) in radikalno prostatektomijo (3,3%).
Your doctor may start you on a lower dose (25 mg) of Sildenafil Actavis. 
Zdravnik vam bo sprva morda predpisal manjši odmerek (25 mg) zdravila Sildenafil Actavis.
The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure <90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases). 
Varnost sildenafila pri naslednjih podskupinah bolnikov ni raziskana, zato je njegova uporaba v teh skupinah kontraindicirana: huda okvara jeter, hipotenzija (krvni tlak <90/50 mmHg), nedavna možganska kap ali miokardni infarkt in znane hereditarne degenerativne bolezni mrežnice, npr. retinitis pigmentosa (majhen del teh bolnikov ima genetske motnje mrežničnih fosfodiesteraz).
Tell your doctor if you are taking any of these medicines which are often given for relief of angina pectoris (or “chest pain”). 
Zdravniku morate povedati, če jemljete katero od teh zdravil, ki se pogosto uporabljajo za ublažitev angine pektoris (bolečin v prsih).
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50>150 µM). 
Sildenafil je šibek zaviralec izoencimov 1A2, 2C9, 2C19, 2D6, 2E1 in 3A4 citokroma P450 (IC50>150 mikroM).
This is most likely to happen within 4 hours after taking Sildenafil Actavis. 
Verjetnost, da se to zgodi je največja v 4 urah po uporabi zdravila Sildenafil Actavis.
Adverse reactions from post-marketing surveillance has been gathered covering an estimated period >10 years. 
Zbrana poročila o neželenih učinkih v obdobju postmarketinškega nadzora zajemajo obdobje več kot 10 let.
- Seizures or fits - this occurs rarely 
· Konvulzije ali napadi - to se zgodi redko
Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness, which may be caused by low blood pressure upon sitting or standing up quickly. 
Nekaterim bolnikom, ki jemljejo antagonist adrenergičnih receptorjev alfa za zdravljenje visokega krvnega tlaka ali zaradi povečane prostate, se lahko v stoje pojavi omotica ali vrtoglavica; to je lahko posledica nizkega krvnega tlaka, če se bolnik hitro usede (iz ležečega položaja) ali vstane.
Plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil. 
Koncentracija tega presnovka v plazmi je približno 40% koncentracije sildenafila.
In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment. 
Pri prostovoljcih z blago do zmerno cirozo jeter (Child-Pugh A in B) je bil očistek sildenafila zmanjšan, kar je povzročilo povečanje AUC (84%) in Cmaks (47%) v primerjavi s prostovoljci primerljive starosti brez okvare jeter.
Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, cimetidine). 
Populacijska farmakokinetična analiza podatkov kliničnih preskušanj je pokazala, da se očistek sildenafila zmanjša pri sočasni uporabi zaviralcev CYP3A4 (npr. ketokonazola, eritromicina, cimetidina).
This is most likely to occur within 4 hours post sildenafil dosing (see sections 4.2 and 4.4). 
Verjetnost tega je največja v 4 urah po uporabi sildenafila (glejte poglavji 4.2 in 4.4).
Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1). 
Sildenafil deluje vazodilatacijsko in zato povzroči blago in prehodno znižanje krvnega tlaka (glejte poglavje 5.1).
Doses of 200 mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased. 
Odmerek 200 mg ni bil bolj učinkovit, povečala pa se je pogostnost neželenih učinkov (glavobola, zardevanja, omotice, dispepsije, zamašenega nosu, sprememb vida).
In a separate RigiScan study, sildenafil was still able to produce an erection in response to sexual stimulation 4-5 hours post-dose. 
V posebni študiji z RigiScanom so ugotovili, da lahko sildenafil povzroči erekcijo v odziv na spolno stimulacijo še 4 do 5 ur po odmerku.
The following groups were not well represented or excluded from clinical trials: patients with pelvic surgery, patients post-radiotherapy, patients with severe renal or hepatic impairment and patients with certain cardiovascular conditions (see section 4.3). 
Nezadostno zajete ali izključene iz kliničnih preskušanj so bile naslednje skupine: bolniki po operacijah na medenici, po radioterapiji, s hudo okvaro ledvic ali jeter in bolniki z določenimi kardiovaskularnimi boleznimi (glejte poglavje 4.3).
You should not use Sildenafil Actavis with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors. 
Zdravila Sildenafil Actavis ne smete uporabljati skupaj z zdravili za zdravljenje pljučne artetrijske hipertenzije (PAH), ki vsebujejo sildenafil ali katerekoli druge zaviralce PDE5.
These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers (see section 5.1). 
To dodatno znižanje krvnega tlaka je bilo po velikosti podobno kot med uporabo samega sildenafila pri zdravih prostovoljcih glejte poglavje 5.1).
Do not use this medicine after the expiry date which is stated on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
In a penile plethysmography (RigiScan) study of fasted patients, the median time to onset for those who obtained erections of 60% rigidity (sufficient for sexual intercourse) was 25 minutes (range 12-37 minutes) on sildenafil. 
V študiji s pletizmografijo penisa (RigiScan) in uporabo sildenafila na prazen želodec je bil mediani čas do začetka delovanja pri bolnikih, ki so dosegli erekcijo s 60% čvrstostjo (zadostno za spolni odnos), 25 minut (razpon: 12 do 37 minut).
In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n=9), sildenafil (single dose, 100 mg) demonstrated no significant changes in the visual tests conducted (visual acuity, Amsler grid, colour discrimination simulated traffic light, Humphrey perimeter and photostress). 
V majhni s placebom kontrolirani študiji pri bolnikih s potrjeno zgodnjo starostno degeneracijo makule (n=9) enkraten odmerek sildenafila (100 mg) ni povzročil pomembnih sprememb na opravljenih preiskavah vida (ostrina vida, Amslerjeva mrežica, razločevanje barv na simuliranem semaforju, Humphreyev perimeter in fotostres).
Reykjavíkurvegi 78 IS-220 Hafnarfjörður Iceland 
Reykjavíkurvegi 78 IS-220 Hafnarfjörður Islandija
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http: //www.ema.europa.eu/.
Other medicines and Sildenafil Actavis 
Druga zdravila in Sildenafil Actavis
This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity. 
To je motnja, pri kateri moški ne more doseči ali ohraniti otrdelosti spolnega uda, ki bi zadoščala za spolno dejavnost.
In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased. 
V študijah enega odmerka pri zdravih prostovoljcih so bili neželeni učinki pri odmerkih do 800 mg podobni kot pri manjših odmerkih, bili pa so pogostejši in izrazitejši.
In addition, the frequency of medically important adverse reactions reported from post-marketing experience is included as not known. 
Poleg tega so vključeni medicinsko pomembni neželeni učinki, opisani med postmarketinškim obdobjem; njihova pogostnost je navedena kot "ni znano".
In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility. 
Še posebno pa je selektivnost sildenafila več kot 4.000-krat večja za PDE5 kakor za PDE3-za cAMP specifično izoobliko fosfodiesteraze, ki sodeluje v uravnavanju krčljivosti srca.
In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. 
Pri normalnih zdravih moških prostovoljcih azitromicin (3 dni po 500 mg na dan) ni vplival na AUC, Cmaks, tmaks, konstanto hitrosti eliminacije ali na poznejši razpolovni čas sildenafila oz. njegovega glavnega presnovka v obtoku.
In volunteers with mild to moderate renal impairment (creatinine clearance=30-80 mL/min), the pharmacokinetics of sildenafil were not altered after receiving a 50 mg single oral dose. 
Pri prostovoljcih z blago do zmerno okvaro ledvic (očistek kreatinina = 30 do 80 mL/min) se farmakokinetika sildenafila po enkratnem peroralnem odmerku 50 mg ni spremenila.
Titanium dioxide (E171) Macrogol 6000 
Filmska obloga: hipromeloza titanov dioksid (E171) makrogol 6000 indigotin (E132)
Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates). 
Čeprav niso bile opravljene specifične študije interakcij za vsa zdravila, populacijska farmakokinetična analiza ni pokazala vpliva na farmakokinetiko sildenafila pri sočasnem zdravljenju z zdravili iz skupine zaviralcev CYP2C9 (npr. tolbutamidom, varfarinom, fenitoinom) ali zaviralcev CYP2D6 (npr. selektivnimi zaviralci sprejema serotonina, tricikličnimi antidepresivi), tiazidi in sorodnimi diuretiki, diuretiki Henlejeve zanke in diuretiki, ki ohranjajo kalij, zaviralci ACE, zaviralci kalcijevih kanalčkov, antagonisti adrenergičnih receptorjev beta ali induktorji presnove s CYP450 (npr. rifampicinom ali barbiturati).
Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g., aortic stenosis, hypertrophic obstructive cardiomyopathy), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure. 
Med bolnike z večjo občutljivostjo za vazodilatatorje spadajo bolniki z obstrukcijo iztoka iz levega prekata (npr. z aortno stenozo, hipertrofično obstruktivno kardiomiopatijo) ali z redkim sindromom multiple sistemske atrofije, ki se kaže kot huda okvara avtonomnega uravnavanja krvnega tlaka.
Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately 
Zaradi starostnih razlik v vezavi na beljakovine se je koncentracija prostega sildenafila v plazmi povečala za približno 40%.
Sildenafil Actavis tablets may interfere with some medicines, especially those used to treat chest pain. 
Tablete Sildenafil Actavis lahko medsebojno delujejo z nekaterimi zdravili, zlasti z zdravili proti angini pektoris.
Sildenafil Actavis is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4). 
Zdravilo Sildenafil Actavis je kontraindicirano pri bolnikih, ki so izgubili vid na enem očesu zaradi nearteritične anteriorne ishemične optične nevropatije (NAION), tudi če ta dogodek ni bil povezan s predhodnim jemanjem zaviralcev PDE5 (glejte poglavje 4.4).
The mean AUC and Cmax of the N-desmethyl metabolite increased 126% and 73% respectively, compared to age-matched volunteers with no renal impairment. 
Povprečna AUC N-dezmetilnega presnovka se je povečala za 126%, povprečna Cmaks pa za 73% v primerjavi s starostno primerljivimi prostovoljci brez okvare ledvic.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (>70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline. 
V študiji hemodinamskih učinkov enkratnega peroralnega odmerka 100 mg sildenafila pri 14 bolnikih s hudo boleznijo koronarnih arterij (> 70 % stenoza vsaj ene koronarne arterije) se je povprečni sistolični tlak v mirovanju v primerjavi z izhodiščem znižal za 7 %, povprečni diastolični tlak v mirovanju pa za 6 %.
Agents for the treatment of erectile dysfunction, including sildenafil, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia). 
Zdravila za zdravljenje erektilne disfunkcije, vključno s sildenafilom, je treba previdno uporabljati pri bolnikih z anatomskimi deformacijami penisa (npr. z angulacijo, kavernozno fibrozo ali Peyronijevo boleznijo) in pri bolnikih z določenimi boleznimi, ki povzročajo nagnjenost k priapizmu (npr. s srpastocelično anemijo, multiplim mielomom ali levkemijo).
The tablets are provided in blister packs containing 1, 2, 4, 8, 12 or 24 tablets. 
Tablete so na voljo v pretisnih omotih, ki vsebujejo po 1, 2, 4, 8, 12 ali 24 tablet.
Sildenafil Actavis is a treatment for adult men with erectile dysfunction, sometimes known as impotence. 
Zdravilo Sildenafil Actavis je zdravilo za odrasle moške z erektilno disfunkcijo, imenovano tudi impotenca.
You should not use Sildenafil Actavis with any other oral or local treatments for erectile dysfunction. 
Zdravila Sildenafil Actavis ne smete uporabljati skupaj z nobenim drugim peroralnim ali lokalnim zdravilom za erektilno disfunkcijo.
A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered. 
Pred odločitvijo za farmakološko zdravljenje je treba z anamnezo in kliničnim pregledom diagnosticirati erektilno disfunkcijo in ugotoviti možne osnovne vzroke zanjo.
Sildenafil Actavis should not be administered to men with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. 
Zdravila Sildenafil Actavis ne smejo jemati moški z redkimi prirojenimi motnjami, kot so galaktozna intoleranca, laponska oblika zmanjšane aktivnosti laktaze ali malabsorbcijo glukoze-galaktoze.
In healthy volunteers receiving sildenafil (100 mg single dose), less than 0.0002% (average 188 ng) of the administered dose was present in ejaculate 90 minutes after dosing. 
Pri zdravih prostovoljcih, ki so dobili sildenafil (en odmerek 100 mg), je bilo v ejakulatu 90 minut po uporabi manj kot 0,0002% (povprečno 188 ng) uporabljenega odmerka.
The mean maximum decreases in supine systolic blood pressure following 100 mg oral dosing of sildenafil was 8.4 mmHg. 
Povprečno največje znižanje sistoličnega krvnega tlaka leže je bilo po peroralnem odmerku 100 mg sildenafila 8,4 mmHg.
The safety and efficacy of combinations of sildenafil with other PDE5 inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil (REVATIO), or other treatments for erectile dysfunction have not been studied. 
Varnost in učinkovitost kombinacije sildenafila z drugimi zaviralci PDE5, drugimi zdravili proti pljučni arterijski hipertenziji (PAH), ki vsebujejo sildenafil (REVATIO), ali drugimi zdravili za zdravljenje erektilne disfunkcije nista raziskani, zato uporaba takšnih kombinacij ni priporočena.
Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75%). 
V vseh preskušanjih skupaj so bili deleži bolnikov, ki so s sildenafilom navajali izboljšanje, naslednji: bolniki s psihogeno erektilno disfunkcijo 84%, mešano erektilno disfunkcijo 77%, organsko erektilno disfunkcijo 68%, starejši 67%, bolniki s sladkorno boleznijo 59%, ishemično boleznijo srca 69%, zvišanim krvnim tlakom 68%, TURP 61%, radikalno prostatektomijo 43%, poškodbo hrbtenjače 83%, depresijo 75%.
When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension. 
Med sočasno uporabo sildenafila in doksazosina pri bolnikih, stabiliziranih na zdravljenju z doksazosinom, so v redkih primerih poročali o simptomatski posturalni hipotenziji.